Tumor Necrosis Factor Α Induces a Metalloprotease-Disintegrin, ADAM8
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Prion Fragment Peptides Are Digested with Membrane Type Matrix Metalloproteinases and Acquire Enzyme Resistance Through Cu2+-Binding
Biomolecules 2014, 4, 510-526; doi:10.3390/biom4020510 OPEN ACCESS biomolecules ISSN 2218-273X www.mdpi.com/journal/biomolecules/ Article Prion Fragment Peptides Are Digested with Membrane Type Matrix Metalloproteinases and Acquire Enzyme Resistance through Cu2+-Binding Aya Kojima 1,2, Motomi Konishi 1 and Toshifumi Akizawa 1,* 1 Analytical Chemistry, Pharmaceutical Science, Setsunan University, 45-1 Nagaotoge-cho, Hirakata, Osaka 573-0101, Japan; E-Mails: [email protected] (A.K.); [email protected] (M.K.) 2 Division of Cellular and Molecular Biology, Department of Cancer Biology, Institute of Medical Science, The University of Tokyo, 4-6-1 Shirokanedai, Minato-ku, Tokyo 180-8639, Japan * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel./Fax: +81-72-866-3129. Received: 31 January 2014; in revised form: 2 April 2014 / Accepted: 11 April 2014 / Published: 8 May 2014 Abstract: Prions are the cause of neurodegenerative disease in humans and other mammals. The structural conversion of the prion protein (PrP) from a normal cellular protein (PrPC) to a protease-resistant isoform (PrPSc) is thought to relate to Cu2+ binding to histidine residues. In this study, we focused on the membrane-type matrix metalloproteinases (MT-MMPs) such as MT1-MMP and MT3-MMP, which are expressed in the brain as PrPC-degrading proteases. We synthesized 21 prion fragment peptides. Each purified peptide was individually incubated with recombinant MT1-MMP or MT3-MMP in the presence or absence of Cu2+ and the cleavage sites determined by LC-ESI-MS analysis. Recombinant MMP-7 and human serum (HS) were also tested as control. -
Supporting Online Material
1 2 3 4 5 6 7 Supplementary Information for 8 9 Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic 10 retinopathy 11 12 *Samuel A. Mills, *Andrew I. Jobling, *Michael A. Dixon, Bang V. Bui, Kirstan A. Vessey, Joanna A. Phipps, 13 Ursula Greferath, Gene Venables, Vickie H.Y. Wong, Connie H.Y. Wong, Zheng He, Flora Hui, James C. 14 Young, Josh Tonc, Elena Ivanova, Botir T. Sagdullaev, Erica L. Fletcher 15 * Joint first authors 16 17 Corresponding author: 18 Prof. Erica L. Fletcher. Department of Anatomy & Neuroscience. The University of Melbourne, Grattan St, 19 Parkville 3010, Victoria, Australia. 20 Email: [email protected] ; Tel: +61-3-8344-3218; Fax: +61-3-9347-5219 21 22 This PDF file includes: 23 24 Supplementary text 25 Figures S1 to S10 26 Tables S1 to S7 27 Legends for Movies S1 to S2 28 SI References 29 30 Other supplementary materials for this manuscript include the following: 31 32 Movies S1 to S2 33 34 35 36 1 1 Supplementary Information Text 2 Materials and Methods 3 Microglial process movement on retinal vessels 4 Dark agouti rats were anaesthetized, injected intraperitoneally with rhodamine B (Sigma-Aldrich) to label blood 5 vessels and retinal explants established as described in the main text. Retinal microglia were labelled with Iba-1 6 and imaging performed on an inverted confocal microscope (Leica SP5). Baseline images were taken for 10 7 minutes, followed by the addition of PBS (10 minutes) and then either fractalkine or fractalkine + candesartan 8 (10 minutes) using concentrations outlined in the main text. -
ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease
International Journal of Molecular Sciences Review ADAM10 Site-Dependent Biology: Keeping Control of a Pervasive Protease Francesca Tosetti 1,* , Massimo Alessio 2, Alessandro Poggi 1,† and Maria Raffaella Zocchi 3,† 1 Molecular Oncology and Angiogenesis Unit, IRCCS Ospedale Policlinico S. Martino Largo R. Benzi 10, 16132 Genoa, Italy; [email protected] 2 Proteome Biochemistry, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] 3 Division of Immunology, Transplants and Infectious Diseases, IRCCS San Raffaele Scientific Institute, 20132 Milan, Italy; [email protected] * Correspondence: [email protected] † These authors contributed equally to this work as last author. Abstract: Enzymes, once considered static molecular machines acting in defined spatial patterns and sites of action, move to different intra- and extracellular locations, changing their function. This topological regulation revealed a close cross-talk between proteases and signaling events involving post-translational modifications, membrane tyrosine kinase receptors and G-protein coupled recep- tors, motor proteins shuttling cargos in intracellular vesicles, and small-molecule messengers. Here, we highlight recent advances in our knowledge of regulation and function of A Disintegrin And Metalloproteinase (ADAM) endopeptidases at specific subcellular sites, or in multimolecular com- plexes, with a special focus on ADAM10, and tumor necrosis factor-α convertase (TACE/ADAM17), since these two enzymes belong to the same family, share selected substrates and bioactivity. We will discuss some examples of ADAM10 activity modulated by changing partners and subcellular compartmentalization, with the underlying hypothesis that restraining protease activity by spatial Citation: Tosetti, F.; Alessio, M.; segregation is a complex and powerful regulatory tool. -
Gene Pval Qval Log2 Fold Change AAMP 0.895690332 0.952598834
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance Supplemental material placed on this supplemental material which has been supplied by the author(s) Gut Gene pval qval Log2 Fold Change AAMP 0.895690332 0.952598834 -0.21 ABI3BP 0.002302151 0.020612283 0.465 ACHE 0.103542461 0.296385483 -0.16 ACTG2 2.99E-07 7.68E-05 3.195 ACVR1 0.071431098 0.224504378 0.19 ACVR1C 0.978209579 0.995008423 0.14 ACVRL1 0.006747504 0.042938663 0.235 ADAM15 0.158715519 0.380719469 0.285 ADAM17 0.978208929 0.995008423 -0.05 ADAM28 0.038932876 0.152174187 -0.62 ADAM8 0.622964796 0.790251882 0.085 ADAM9 0.122003358 0.329623107 0.25 ADAMTS1 0.180766659 0.414256926 0.23 ADAMTS12 0.009902195 0.05703885 0.425 ADAMTS8 4.60E-05 0.001169089 1.61 ADAP1 0.269811968 0.519388039 0.075 ADD1 0.233702809 0.487695826 0.11 ADM2 0.012213453 0.066227879 -0.36 ADRA2B 0.822777921 0.915518785 0.16 AEBP1 0.010738542 0.06035531 0.465 AGGF1 0.117946691 0.320915024 -0.095 AGR2 0.529860903 0.736120272 0.08 AGRN 0.85693743 0.928047568 -0.16 AGT 0.006849995 0.043233572 1.02 AHNAK 0.006519543 0.042542779 0.605 AKAP12 0.001747074 0.016405449 0.51 AKAP2 0.409929603 0.665919397 0.05 AKT1 0.95208288 0.985354963 -0.085 AKT2 0.367391504 0.620376005 0.055 AKT3 0.253556844 0.501934205 0.07 ALB 0.064833867 0.21195036 -0.315 ALDOA 0.83128831 0.918352939 0.08 ALOX5 0.029954404 0.125352668 -0.3 AMH 0.784746815 0.895196237 -0.03 ANG 0.050500474 0.181732067 0.255 ANGPT1 0.281853305 0.538528647 0.285 ANGPT2 0.43147281 0.675272487 -0.15 ANGPTL2 0.001368876 0.013688762 0.71 ANGPTL4 0.686032669 0.831882134 -0.175 ANPEP 0.019103243 0.089148466 -0.57 ANXA2P2 0.412553021 0.665966092 0.11 AP1M2 0.87843088 0.944681253 -0.045 APC 0.267444505 0.516134751 0.09 APOD 1.04E-05 0.000587404 0.985 APOE 0.023722987 0.104981036 -0.395 APOH 0.336334555 0.602273505 -0.065 Sundar R, et al. -
R&D Assay for Alzheimer's Disease
R&DR&D assayassay forfor Alzheimer’sAlzheimer’s diseasedisease Target screening⳼ Ⲽ㬔 antibody array, ᢜ⭉㬔 ⸽ἐⴐ Amyloid β-peptide Alzheimer’s disease⯸ ኸᷠ᧔ ᆹ⸽ inhibitor, antibody, ELISA kit Surwhrph#Surilohu#Dqwlerg|#Duud| 6OUSFBUFE 1."5SFBUFE )41 $3&# &3, &3, )41 $3&# &3, &3, 壤伡庰䋸TBNQMF ɅH 侴䋸嵄䍴䋸BOBMZUFT䋸䬱娴哜塵 1$ 1$ 1$ 1$ 5IFNPTUSFGFSFODFEBSSBZT 1$ 1$ QQ α 34, .4, 503 Q α 34, .4, 503 %SVHTDSFFOJOH0òUBSHFUFòFDUT0ATHWAY涭廐 6OUSFBUFE 堄币䋸4BNQMF侴䋸8FTUFSOPS&-*4"䍘䧽 1."5SFBUFE P 8FTUFSOCMPU廽喜儤应侴䋸0, Z 4VCTUSBUF -JHIU )31DPOKVHBUFE1BO "OUJQIPTQIPUZSPTJOF .FBO1JYFM%FOTJUZ Y $BQUVSF"OUJCPEZ 5BSHFU"OBMZUF "SSBZ.FNCSBOF $3&# &3, &3, )41 .4, Q α 34, 503 Human XL Cytokine Array kit (ARY022, 102 analytes) Adiponectin,Aggrecan,Angiogenin,Angiopoietin-1,Angiopoietin-2,BAFF,BDNF,Complement,Component C5/C5a,CD14,CD30,CD40L, Chitinase 3-like 1,Complement Factor D,C-Reactive Protein,Cripto-1,Cystatin C,Dkk-1,DPPIV,EGF,EMMPRIN,ENA-78,Endoglin, Fas L,FGF basic,FGF- 7,FGF-19,Flt-3 L,G-CSF,GDF-15,GM-CSF,GRO-α,Grow th Hormone,HGF,ICAM-1,IFN-γ,IGFBP-2,IGFBP-3, IL-1α,IL-1β, IL-1ra,IL-2,IL-3,IL-4,IL- 5,IL-6,IL-8, IL-10,IL-11,IL-12, IL-13,IL-15,IL-16,IL-17A,IL-18 BPa,IL-19,IL-22, IL-23,IL-24,IL-27, IL-31,IL-32α/β/γ,IL-33,IL-34,IP-10,I-TAC,Kallikrein 3,Leptin,LIF,Lipocalin-2,MCP-1,MCP-3,M-CSF,MIF,MIG,MIP-1α/MIP-1β,MIP-3α,MIP-3β,MMP-9, Myeloperoxidase,Osteopontin, p70, PDGF-AA, PDGF-AB/BB,Pentraxin-3, PF4, RAGE, RANTES,RBP4,Relaxin-2, Resistin,SDF-1α,Serpin E1, SHBG, ST2, TARC,TFF3,TfR,TGF- ,Thrombospondin-1,TNF-α, uPAR, VEGF, Vitamin D BP Human Protease (34 analytes) / -
Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association Between BMI and Adult-Onset Non- Atopic
Supplementary Material DNA Methylation in Inflammatory Pathways Modifies the Association between BMI and Adult-Onset Non- Atopic Asthma Ayoung Jeong 1,2, Medea Imboden 1,2, Akram Ghantous 3, Alexei Novoloaca 3, Anne-Elie Carsin 4,5,6, Manolis Kogevinas 4,5,6, Christian Schindler 1,2, Gianfranco Lovison 7, Zdenko Herceg 3, Cyrille Cuenin 3, Roel Vermeulen 8, Deborah Jarvis 9, André F. S. Amaral 9, Florian Kronenberg 10, Paolo Vineis 11,12 and Nicole Probst-Hensch 1,2,* 1 Swiss Tropical and Public Health Institute, 4051 Basel, Switzerland; [email protected] (A.J.); [email protected] (M.I.); [email protected] (C.S.) 2 Department of Public Health, University of Basel, 4001 Basel, Switzerland 3 International Agency for Research on Cancer, 69372 Lyon, France; [email protected] (A.G.); [email protected] (A.N.); [email protected] (Z.H.); [email protected] (C.C.) 4 ISGlobal, Barcelona Institute for Global Health, 08003 Barcelona, Spain; [email protected] (A.-E.C.); [email protected] (M.K.) 5 Universitat Pompeu Fabra (UPF), 08002 Barcelona, Spain 6 CIBER Epidemiología y Salud Pública (CIBERESP), 08005 Barcelona, Spain 7 Department of Economics, Business and Statistics, University of Palermo, 90128 Palermo, Italy; [email protected] 8 Environmental Epidemiology Division, Utrecht University, Institute for Risk Assessment Sciences, 3584CM Utrecht, Netherlands; [email protected] 9 Population Health and Occupational Disease, National Heart and Lung Institute, Imperial College, SW3 6LR London, UK; [email protected] (D.J.); [email protected] (A.F.S.A.) 10 Division of Genetic Epidemiology, Medical University of Innsbruck, 6020 Innsbruck, Austria; [email protected] 11 MRC-PHE Centre for Environment and Health, School of Public Health, Imperial College London, W2 1PG London, UK; [email protected] 12 Italian Institute for Genomic Medicine (IIGM), 10126 Turin, Italy * Correspondence: [email protected]; Tel.: +41-61-284-8378 Int. -
Α-Secretase Nonsense Mutation (ADAM10 Tyr167*) in Familial
Agüero et al. Alzheimer's Research & Therapy (2020) 12:139 https://doi.org/10.1186/s13195-020-00708-0 RESEARCH Open Access α-Secretase nonsense mutation (ADAM10 Tyr167*) in familial Alzheimer’s disease Pablo Agüero1, María José Sainz1, María-Salud García-Ayllón2,3,4, Javier Sáez-Valero2,3, Raquel Téllez5, Rosa Guerrero-López6, Julián Pérez-Pérez7, Adriano Jiménez-Escrig8 and Estrella Gómez-Tortosa1* Abstract Background: The disintegrin metalloproteinase 10 (ADAM10) is the main α-secretase acting in the non- amyloidogenic processing of APP. Some ADAM10 gene variants have been associated with higher susceptibility to develop late-onset AD, though clear clinical-genetic correlates remain elusive. Methods: Clinical-genetic and biomarker study of a first family with early- and late-onset AD associated with a nonsense ADAM10 mutation (p.Tyr167*). CSF analysis included AD core biomarkers, as well as Western blot of ADAM10 species and sAPPα and sAPPβ peptides. We evaluate variant’s pathogenicity, pattern of segregation, and further screened for the p.Tyr167* mutation in 197 familial AD cases from the same cohort, 200 controls from the same background, and 274 AD cases from an independent Spanish cohort. Results: The mutation was absent from public databases and segregated with the disease. CSF Aβ42, total tau, and phosphorylated tau of affected siblings were consistent with AD. The predicted haploinsufficiency effect of the nonsense mutation was supported by (a) ADAM10 isoforms in CSF decreased around 50% and (b) 70% reduction of CSF sAPPα peptide, both compared to controls, while sAPPβ levels remained unchanged. Interestingly, sporadic AD cases had a similar decrease in CSF ADAM10 levels to that of mutants, though their sAPPα and sAPPβ levels resembled those of controls. -
ADAM8 Expression in Invasive Breast Cancer Promotes Tumor Dissemination and Metastasis
ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis Mathilde Romagnoli, Nora Mineva, Michael Polmear, Catharina Conrad, Srimathi Srinivasan, Delphine Loussouarn, Sophie Barillé-Nion, Irene Georgakoudi, Aine Dagg, Enda Mcdermott, et al. To cite this version: Mathilde Romagnoli, Nora Mineva, Michael Polmear, Catharina Conrad, Srimathi Srinivasan, et al.. ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis. EMBO Molecular Medicine, Wiley Open Access, 2014, 6 (2), pp.278-294. 10.1002/emmm.201303373. inserm-02447040 HAL Id: inserm-02447040 https://www.hal.inserm.fr/inserm-02447040 Submitted on 21 Jan 2020 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Research Article ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis Mathilde Romagnoli1, Nora D Mineva1, Michael Polmear2, Catharina Conrad3, Srimathi Srinivasan1, Delphine Loussouarn4, Sophie Barille-Nion4, Irene Georgakoudi2, Aine Dagg5,6, Enda W McDermott6, Michael J Duffy6, Patricia M. McGowan5,6, Uwe Schlomann3, Maddy Parsons7,Jorg€ W Bartsch3 & Gail E Sonenshein1,* Abstract Introduction The transmembrane metalloprotease-disintegrin ADAM8 mediates Cancer metastasis results from a multistep process that selects for cell adhesion and shedding of ligands, receptors and extracellular invasive tumor cells capable of escaping from the primary site and matrix components. -
The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex
The Journal of Neuroscience, April 7, 2010 • 30(14):4833–4844 • 4833 Development/Plasticity/Repair The Disintegrin/Metalloproteinase ADAM10 Is Essential for the Establishment of the Brain Cortex Ellen Jorissen,1,2* Johannes Prox,3* Christian Bernreuther,4 Silvio Weber,3 Ralf Schwanbeck,3 Lutgarde Serneels,1,2 An Snellinx,1,2 Katleen Craessaerts,1,2 Amantha Thathiah,1,2 Ina Tesseur,1,2 Udo Bartsch,5 Gisela Weskamp,6 Carl P. Blobel,6 Markus Glatzel,4 Bart De Strooper,1,2 and Paul Saftig3 1Center for Human Genetics, Katholieke Universiteit Leuven and 2Department for Developmental and Molecular Genetics, Vlaams Instituut voor Biotechnologie (VIB), 3000 Leuven, Belgium, 3Institut fu¨r Biochemie, Christian-Albrechts-Universita¨t zu Kiel, D-24098 Kiel, Germany, 4Institute of Neuropathology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany, 5Department of Ophthalmology, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany, and 6Arthritis and Tissue Degeneration Program, Hospital for Special Surgery, and Departments of Medicine and of Physiology, Systems Biology and Biophysics, Weill Medical College of Cornell University, New York, New York 10021 The metalloproteinase and major amyloid precursor protein (APP) ␣-secretase candidate ADAM10 is responsible for the shedding of ,proteins important for brain development, such as cadherins, ephrins, and Notch receptors. Adam10 ؊/؊ mice die at embryonic day 9.5 due to major defects in development of somites and vasculogenesis. To investigate the function of ADAM10 in brain, we generated Adam10conditionalknock-out(cKO)miceusingaNestin-Crepromotor,limitingADAM10inactivationtoneuralprogenitorcells(NPCs) and NPC-derived neurons and glial cells. The cKO mice die perinatally with a disrupted neocortex and a severely reduced ganglionic eminence, due to precocious neuronal differentiation resulting in an early depletion of progenitor cells. -
Airway Inflammation in Mice Adam8 Limits the Development of Allergic
Adam8 Limits the Development of Allergic Airway Inflammation in Mice Martin D. Knolle, Takahiro Nakajima, Anja Hergrueter, Kushagra Gupta, Francesca Polverino, Vanessa J. Craig, This information is current as Susanne E. Fyfe, Muhammad Zahid, Perdita Permaul, of October 2, 2021. Manuela Cernadas, Gilbert Montano, Yohannes Tesfaigzi, Lynette Sholl, Lester Kobzik, Elliot Israel and Caroline A. Owen J Immunol 2013; 190:6434-6449; Prepublished online 13 May 2013; Downloaded from doi: 10.4049/jimmunol.1202329 http://www.jimmunol.org/content/190/12/6434 http://www.jimmunol.org/ Supplementary http://www.jimmunol.org/content/suppl/2013/05/13/jimmunol.120232 Material 9.DC1 References This article cites 77 articles, 18 of which you can access for free at: http://www.jimmunol.org/content/190/12/6434.full#ref-list-1 Why The JI? Submit online. by guest on October 2, 2021 • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2013 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. The Journal of Immunology Adam8 Limits the Development of Allergic Airway Inflammation in Mice Martin D. -
ADAM10 Controls Collagen Signaling and Cell Migration on Collagen by Shedding the Ectodomain of Discoidin Domain Receptor 1 (DDR1)
M BoC | ARTICLE ADAM10 controls collagen signaling and cell migration on collagen by shedding the ectodomain of discoidin domain receptor 1 (DDR1) Yasuyuki Shitomia, Ida B. Thøgersenb, Noriko Itoa, Birgit Leitingerc, Jan J. Enghildb, and Yoshifumi Itoha aKennedy Institute of Rheumatology, Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford OX3 7FY, United Kingdom; bDepartment of Molecular Biology and Genetics, University of Aarhus, DK-8000 Aarhus C, Denmark; cNational Heart and Lung Institute, Imperial College London, London SW7 2AZ, United Kingdom ABSTRACT Discoidin domain receptor 1 (DDR1) is a receptor tyrosine kinase that binds and Monitoring Editor transmits signals from various collagens in epithelial cells. However, how DDR1–dependent Jean E. Schwarzbauer signaling is regulated has not been understood. Here we report that collagen binding in- Princeton University duces ADAM10-dependent ectodomain shedding of DDR1. DDR1 shedding is not a result of Received: Oct 21, 2014 an activation of its signaling pathway, since DDR1 mutants defective in signaling were shed Revised: Dec 4, 2014 in an efficient manner. DDR1 and ADAM10 were found to be in a complex on the cell surface, Accepted: Dec 16, 2014 but shedding did not occur unless collagen bound to DDR1. Using a shedding-resistant DDR1 mutant, we found that ADAM10-dependent DDR1 shedding regulates the half-life of colla- gen-induced phosphorylation of the receptor. Our data also revealed that ADAM10 plays an important role in regulating DDR1-mediated cell adhesion to achieve efficient cell migration on collagen matrices. INTRODUCTION Extracellular matrix (ECM) is essential in multicellular organisms to discoidin domain receptors (DDRs), glycoprotein VI, leukocyte-asso- maintain functional tissue structures; it acts as scaffolding to support ciated, immunoglobulin-like receptors, and mannose receptors such cell migration and as a reservoir for growth factors. -
Strategies to Target ADAM17 in Disease: from Its Discovery to the Irhom Revolution
molecules Review Strategies to Target ADAM17 in Disease: From Its Discovery to the iRhom Revolution Matteo Calligaris 1,2,†, Doretta Cuffaro 2,†, Simone Bonelli 1, Donatella Pia Spanò 3, Armando Rossello 2, Elisa Nuti 2,* and Simone Dario Scilabra 1,* 1 Proteomics Group of Fondazione Ri.MED, Research Department IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), Via E. Tricomi 5, 90145 Palermo, Italy; [email protected] (M.C.); [email protected] (S.B.) 2 Department of Pharmacy, University of Pisa, Via Bonanno 6, 56126 Pisa, Italy; [email protected] (D.C.); [email protected] (A.R.) 3 Università degli Studi di Palermo, STEBICEF (Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche), Viale delle Scienze Ed. 16, 90128 Palermo, Italy; [email protected] * Correspondence: [email protected] (E.N.); [email protected] (S.D.S.) † These authors contributed equally to this work. Abstract: For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as the tumor necrosis factor convertase, it has been considered a major drug target, especially in the context of inflammatory diseases and cancer. Nevertheless, the development of drugs targeting ADAM17 has been harder than expected. This has generally been due to its multifunctionality, with over 80 different transmembrane proteins other than tumor necrosis factor α (TNF) being released by ADAM17, and its structural similarity to other metalloproteinases. This review provides an overview of the different roles of ADAM17 in disease and the effects of its ablation in a number of in vivo models of pathological conditions.